- Home
- RCKT vs ADCT Comparison
RCKT vs ADCT Comparison
Compare RCKT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- ADCT
- Stock Information
- Founded
- RCKT 1999
- ADCT 2011
- Country
- RCKT United States
- ADCT Switzerland
- Employees
- RCKT N/A
- ADCT N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- ADCT Health Care
- Exchange
- RCKT Nasdaq
- ADCT Nasdaq
- Market Cap
- RCKT 328.6M
- ADCT 380.2M
- IPO Year
- RCKT N/A
- ADCT 2020
- Fundamental
- Price
- RCKT $3.88
- ADCT $4.21
- Analyst Decision
- RCKT Buy
- ADCT Strong Buy
- Analyst Count
- RCKT 13
- ADCT 6
- Target Price
- RCKT $12.88
- ADCT $7.60
- AVG Volume (30 Days)
- RCKT 3.1M
- ADCT 1.1M
- Earning Date
- RCKT 11-03-2025
- ADCT 11-07-2025
- Dividend Yield
- RCKT N/A
- ADCT N/A
- EPS Growth
- RCKT N/A
- ADCT N/A
- EPS
- RCKT N/A
- ADCT N/A
- Revenue
- RCKT N/A
- ADCT $77,246,000.00
- Revenue This Year
- RCKT N/A
- ADCT $13.47
- Revenue Next Year
- RCKT $3,592.75
- ADCT $5.88
- P/E Ratio
- RCKT N/A
- ADCT N/A
- Revenue Growth
- RCKT N/A
- ADCT 15.73
- 52 Week Low
- RCKT $2.19
- ADCT $1.05
- 52 Week High
- RCKT $18.17
- ADCT $4.74
- Technical
- Relative Strength Index (RSI)
- RCKT 56.54
- ADCT 58.37
- Support Level
- RCKT $3.67
- ADCT $3.92
- Resistance Level
- RCKT $4.06
- ADCT $4.32
- Average True Range (ATR)
- RCKT 0.27
- ADCT 0.23
- MACD
- RCKT 0.00
- ADCT -0.04
- Stochastic Oscillator
- RCKT 43.27
- ADCT 47.56
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).